4D Pharma Names Doyle as Chief Financial Officer
3 January 2022 - - UK-based pharmaceutical company 4D pharma plc (AIM: DDDD) (NASDAQ: LBPS) has appointed John Doyle as chief financial officer, the company said.

Doyle brings over 15 years of experience leading and developing the financial operations, strategy and investor relations functions at public healthcare companies.

Doyle joins 4D pharma after serving as CFO at Chiasma Inc., a publicly traded biopharmaceutical company acquired by Amryt Pharma in 2021.

Prior to Chiasma, Doyle was vice president of Finance and Investor Relations at Verastem Inc., a publicly traded biopharmaceutical company.

Prior to joining Verastem in February 2018, he served as Head of Financial Planning and Analysis at SimpliVity Corp., a software company that was acquired by Hewlett Packard Enterprises in February 2017.

Before that, Doyle was director of Business Unit Financial Planning and Analysis, Early Phase Division, at PAREXEL, a publicly traded pharmaceutical contract research organization.

Earlier in his career, he served in increasingly senior financial planning and analysis roles at Hologic, Inc., a publicly traded provider of medical diagnostic, surgical and imaging products. Doyle holds a B.S. in finance from the University of Massachusetts.

4D pharma is in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.

4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.